These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16857816)

  • 1. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation.
    Sharma SV; Fischbach MA; Haber DA; Settleman J
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4392s-4395s. PubMed ID: 16857816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogene addiction: role of signal attenuation.
    Hübner A; Jaeschke A; Davis RJ
    Dev Cell; 2006 Dec; 11(6):752-4. PubMed ID: 17141149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
    Felsher DW
    Cancer Res; 2008 May; 68(9):3081-6; discussion 3086. PubMed ID: 18451131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogene addiction.
    Weinstein IB; Joe A
    Cancer Res; 2008 May; 68(9):3077-80; discussion 3080. PubMed ID: 18451130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.
    Sharma SV; Gajowniczek P; Way IP; Lee DY; Jiang J; Yuza Y; Classon M; Haber DA; Settleman J
    Cancer Cell; 2006 Nov; 10(5):425-35. PubMed ID: 17097564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor dormancy and oncogene addiction.
    Felsher DW
    APMIS; 2008; 116(7-8):629-37. PubMed ID: 18834407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
    Weinstein IB; Joe AK
    Nat Clin Pract Oncol; 2006 Aug; 3(8):448-57. PubMed ID: 16894390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogene addiction: setting the stage for molecularly targeted cancer therapy.
    Sharma SV; Settleman J
    Genes Dev; 2007 Dec; 21(24):3214-31. PubMed ID: 18079171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is oncogene addiction angiogenesis-dependent?
    Folkman J; Ryeom S
    Cold Spring Harb Symp Quant Biol; 2005; 70():389-97. PubMed ID: 16869776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and death signals can predict tumor response to therapy after oncogene inactivation.
    Tran PT; Bendapudi PK; Lin HJ; Choi P; Koh S; Chen J; Horng G; Hughes NP; Schwartz LH; Miller VA; Kawashima T; Kitamura T; Paik D; Felsher DW
    Sci Transl Med; 2011 Oct; 3(103):103ra99. PubMed ID: 21974937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lineage dependency and lineage-survival oncogenes in human cancer.
    Garraway LA; Sellers WR
    Nat Rev Cancer; 2006 Aug; 6(8):593-602. PubMed ID: 16862190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms for oncogenic activation of the epidermal growth factor receptor.
    Zandi R; Larsen AB; Andersen P; Stockhausen MT; Poulsen HS
    Cell Signal; 2007 Oct; 19(10):2013-23. PubMed ID: 17681753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.
    Kinney EL; Tanida S; Rodrigue AA; Johnson JK; Tompkins VS; Sakamuro D
    J Cell Physiol; 2008 Sep; 216(3):621-31. PubMed ID: 18348166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can't kick that oncogene habit.
    Evan GI
    Cancer Cell; 2006 Nov; 10(5):345-7. PubMed ID: 17097554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
    Bauer S; Yu LK; Demetri GD; Fletcher JA
    Cancer Res; 2006 Sep; 66(18):9153-61. PubMed ID: 16982758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy.
    Evan GI; Christophorou M; Lawlor EA; Ringshausen I; Prescott J; Dansen T; Finch A; Martins C; Murphy D
    Cold Spring Harb Symp Quant Biol; 2005; 70():263-73. PubMed ID: 16869762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirement for Akt-mediated survival in cell transformation by the dbl oncogene.
    Morley S; Wagner J; Kauppinen K; Sherman M; Manor D
    Cell Signal; 2007 Jan; 19(1):211-8. PubMed ID: 16916597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.